Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

Publication | Closed Access

DOI

Citations

References

2017

Year

Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Marková, Michaela Feuring‐Buske, Ulrich Dührsen, Helmut Ostermann,

The Lancet Oncology

Lymphoid NeoplasiaProgression-free SurvivalOncologyRandomised Phase 3PathologyCancer TreatmentImmunotherapyMedicineRadiation OncologyAdvanced Stage HodgkinCancer Research